Clinical-stage biotech developing ion-channel drugs; lead candidate azetukalner targets epilepsy and depression.
Clinical-stage biotech developing ion-channel drugs; lead candidate azetukalner targets epilepsy and depression.
Has no approved product, so revenue is limited to occasional milestone and collaboration payments from partners; trials are funded mainly by cash raised from selling shares. Value rests on late-stage results for azetukalner, which acts on potassium channels in nerve cells.
Moat: none (IP / patents). Pre-commercial biotech; differentiation depends on azetukalner's late-stage trial results.
Headquarters: Vancouver, Canada · Founded: 1996 · Employees: 370
Size Xenon Pharmaceuticals (XENE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.71B, the 1387th largest of 3,085 United States companies the cockpit tracks. Shares closed at $37.75 on 18 Nov 2026.
Performance Over six months the shares fell 31.0%, against +5.7% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 19 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +13.9%).
Capital Return on invested capital runs 188.9 points below its cost of capital (6.6% WACC).
Short interest Short interest is 7.6% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $7.50M | $0 | $0 | $9.43M |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | -$2.32M | $4.96M | -$2.56M | -$3.54M | n/a |
| EBITDA | -$463M | -$371M | -$277M | -$211M | -$128M |
| Net income | -$429M | -$346M | -$234M | -$182M | -$125M |
| Free cash flow | -$352M | -$280M | -$184M | -$151M | -$101M |
| Capital expenditure | $997,090 | $799,000 | $3.08M | $5.62M | $2.89M |
| Total debt | $6.01M | $7.94M | $9.02M | $10.9M | $10.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals XENE | $3.71B | -31% | -100% | n/a | n/a | n/a |
| Neurocrine Biosciences NBIX | $16.5B | +5% | +38% | 25% | 4.4× | -1.5% |
| Supernus Pharmaceuticals SUPN | $6.02B | -41% | +16% | 45% | 4.5× | 6.2% |
| Praxis Precision Medicines PRAX | $8.53B | -9% | -100% | n/a | n/a | n/a |
| Biohaven BHVN | $1.95B | +46% | n/a | n/a | n/a | n/a |
| Axsome Therapeutics AXSM | $7.05B | -42% | +54% | -19% | 8.0× | n/a |
| Jazz Pharmaceuticals Public JAZZ | $15.9B | +4% | +13% | 25% | 4.0× | -2.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | XENE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.1% | -0.2% | 10th highest of 21 |
| 6-month return | -31.0% | +5.7% | 3rd lowest of 19 |
| Distance from 52-week high | -48.0% | -24.8% | 4th lowest of 21 |
| Revenue growth (TTM) | -100.0% | +13.9% | lowest of 18 |
| ROIC minus cost of capital | -188.9 pp | +5.9 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 2.3× | -7.0% | +2.0% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | 5.2× | 34.7% | +159.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 4.2× | 1.2% | +12.1% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 5.1× | 16.2% | -5.8% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 1.8× | -4.1% | -1.0% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 5.5× | 0.9% | +45.1% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% | +5.9% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 0.6× | -4.9% | +7.8% |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% | +4.2% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | 27.6× | 57.4% | +3.1% |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 2.8× | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 20.4× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | 8.4× | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 6.6× | 49.2% | +367.3% |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 3.3× | 4.7% | +7.5% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 3.1× | -2.1% | +12.0% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |